IMP Labeling Requirements: FDA 21 CFR 312 Versus EU Clinical Trials Regulation and GMP Annex 13

Labeling of investigational medicinal products: FDA 21 CFR 312 versus the EU Clinical Trials Regulation and GMP Annex 13

Investigational medicinal products (IMPs) sit outside the marketed-product labeling frameworks, because they are not yet authorized and are supplied only to trial subjects under a protocol. Both the United States and the European Union impose labeling controls, but they start from opposite design philosophies. The FDA rule is a short prohibition-and-warning provision: one mandatory caution statement plus a ban on any claim of safety or efficacy. The EU rule is a detailed positive list of particulars that must be printed on the immediate and outer packaging, scaled to product type and packaging format. Understanding where each regime is prescriptive and where it is silent is the core of getting IMP labeling right across both jurisdictions.

United States: 21 CFR Part 312

For US IND studies the operative label control is 21 CFR 312.6, "Labeling of an investigational new drug," reinforced by the promotion and charging restrictions in 312.7.

The mandatory caution statement. The immediate package of an investigational new drug intended for human use must bear the exact statement: "Caution: New Drug — Limited by Federal (or United States) law to investigational use." ⁶⁰ This is the only affirmative content the regulation compels. FDA does not prescribe a list of identifying particulars (sponsor, batch number, subject number, expiry, storage, and so on); those are left to sponsor discretion and good practice rather than fixed by the rule. ⁶⁰

Prohibitions on the label. The label or labeling must not contain any statement that is false or misleading in any particular, and must not represent that the investigational drug is safe or effective for the purposes for which it is being investigated. ⁶⁰

One narrow exception. The appropriate FDA Center Director may grant an exception or alternative to the caution-statement requirement for specified lots, batches, or other units held in the Strategic National Stockpile, subject to the cited procedures. ⁶⁰

The promotion and commercialization ban (312.7). The labeling rule works together with 312.7, which prohibits a sponsor, investigator, or anyone acting on their behalf from representing in a promotional context that the investigational drug is safe or effective, or otherwise promoting the drug. ⁶¹ The provision also bars commercial distribution and test marketing of an IND, and bars unduly prolonging an investigation after there appear to be sufficient data to support a marketing application, while expressly preserving the full scientific exchange of information, including dissemination of findings in scientific or lay media. ⁶¹ FDA may treat promotion or commercial distribution not justified by the investigation, or not permitted under 312.7, as grounds for terminating the IND. ⁶²

The practical takeaway: US IMP labeling compliance is essentially a two-part test. Is the correct caution statement on the immediate package, and is the label free of any safety/efficacy claim or misleading content. Everything else is a matter of sponsor practice, not regulation.

European Union: the Clinical Trials Regulation regime and the status of Annex 13

The EU picture is more layered, and the reference to "GMP Annex 13" needs a status note. Under the Clinical Trials Regulation (CTR), Regulation (EU) No 536/2014, GMP for IMPs is now governed by Article 63(1) of the Regulation together with Commission Delegated Regulation (EU) 2017/1569, which specifies the principles and guidelines of GMP for IMPs and the arrangements for inspections. ⁷⁰⁷¹¹⁶ The detailed Commission GMP guideline for IMPs states that GMP for investigational medicinal products is set out in Delegated Regulation (EU) 2017/1569 and in those guidelines, and it does not point to the old Annex 13 as the governing text under this regime. ¹⁶ In other words, the historical EudraLex Volume 4 Annex 13 has been superseded as the cited legal basis: since the CTR became applicable, manufacture and import of IMPs (including qualified-person certification and inspections) run on Regulation 536/2014 plus Delegated Regulation 2017/1569. ^70717216

Crucially for labeling, the GMP guideline confirms that IMP labeling must comply with Articles 66 to 69 of Regulation 536/2014, and that the actual list of required labeling information lives in Annex VI to that Regulation. ³ So the modern answer to "what does EU GMP require on an IMP label" is: whatever Annex VI of the CTR requires. The label-content rules that practitioners once looked up in Annex 13 now sit in CTR Annex VI, and the GMP layer (Delegated Regulation 2017/1569) governs how that labeling is applied, controlled, and reconciled under GMP.

What Annex 13 / the current GMP guideline still adds on top of the Annex VI content list are the manufacturing-control expectations around labeling, which matter operationally:

• If an expiry date has to be changed, an additional label must be affixed stating the new expiry date and repeating the batch number and clinical trial reference number. It may cover the old expiry date but must not obscure the original batch number. ²
• Where products are blinded, the assigned expiry date should be that of the shortest-dated product, so that blinding is maintained. ²
• Blinding systems must maintain the blind while still allowing identification of blinded products when necessary (including batch numbers before blinding) and must permit rapid identification in an emergency. ²
• Packaging and labeling of IMPs is recognized as complex and error-prone, especially for blinded products of similar appearance, so precautions against mislabeling (reconciliation, line clearance, in-process control checks by trained staff) must be intensified. ²

What CTR Annex VI requires on the label

Annex VI is a positive-list regime, and the required particulars vary by product type and packaging configuration.

Unauthorized IMPs — full list on immediate and outer packaging

For unauthorized IMPs, the following must appear on both the immediate and outer packaging ⁵¹:

• name, address and telephone number of the main contact for information on the product, the trial, and emergency unblinding ⁵¹
• name of the substance and its strength/potency; in blinded trials, the substance name must appear together with the comparator or placebo on both the IMP and the comparator/placebo packaging ⁵¹
• pharmaceutical form, route of administration, and quantity of dosage units ⁵¹
• batch or code number identifying the contents and the packaging operation ⁵¹
• clinical trial reference code identifying the trial, site, investigator and sponsor, if not given elsewhere ⁵¹
• subject identification number and/or treatment number and, where relevant, visit number ⁵¹
• name of the investigator, if not covered by the main contact or the trial reference code ⁵¹
• directions for use (a leaflet or other explanatory document may substitute) ⁵¹
• "For clinical trial use only" or similar wording ⁵¹
• storage conditions ⁵¹
• period of use, expressed as expiry date or re-test date, in month/year format and unambiguous ⁵¹
• "Keep out of the reach of children," except where the product is used in trials and is not taken home by subjects ⁵¹

Symbols or pictograms may be added, as may additional warnings or handling instructions. ⁵¹

Reduced immediate-packaging labels

Where the immediate and outer packaging remain together and the outer packaging already carries the full particulars, the immediate packaging may carry a reduced set: main contact name; pharmaceutical form, route of administration (may be omitted for oral solid dose forms), quantity of dosage units, and for non-blinded trials the name/identifier and strength/potency; batch or code number; clinical trial reference code; subject identification and/or treatment number and, where relevant, visit number; and the period of use. ⁵¹⁵²

For small immediate packaging (blister packs, ampoules) where all particulars cannot be shown, the outer packaging must bear the full label and the immediate packaging must show at least: main contact name; route of administration (may be omitted for oral solid dose forms) and, in non-blinded trials, name/identifier and strength/potency; batch or code number; clinical trial reference code; subject identification/treatment number and, where relevant, visit number; and the period of use. ⁵²

Authorized IMPs

Authorized IMPs may be labeled either in accordance with Article 66(1) (the Annex VI style) or in accordance with Title V of Directive 2001/83/EC (the normal marketed-product labeling). ⁵⁴ Where the protocol requires it for subject safety or data reliability, additional particulars must appear on the immediate and outer packaging: the main contact name; the clinical trial reference code identifying trial site, investigator, sponsor and subject; and "For clinical trial use only" or similar wording. ⁵⁴

Unauthorized auxiliary medicinal products

For unauthorized auxiliary (non-investigational, e.g. background or rescue) medicinal products, the immediate and outer packaging must carry: main contact name; the product name followed by strength and pharmaceutical form; a qualitative and quantitative statement of active substances per dosage unit; batch or code number; clinical trial reference code; directions for use; "For clinical trial use only"; storage conditions; and the period of use. ⁵²

Permitted simplifications and omissions

Annex VI builds in flexibility: the reduced-label options for combined and small packaging above; omission of route of administration on immediate packaging for oral solid dose forms in reduced-label situations; the blinding rules on how the substance name is presented; and omission of the main contact's address and telephone number where subjects have been given a leaflet or card carrying those details and told to keep it with them at all times. ⁵¹⁵² "Keep out of the reach of children" may be dropped where the product is not taken home. ⁵¹ Particulars other than those in the core paragraph may be omitted from the label and provided by other means, provided subject safety and data reliability are not compromised and this is justified in the protocol. ⁵² Articles 66 and 67 do not apply to radiopharmaceuticals used as diagnostic IMPs or diagnostic auxiliary products, which must instead be labeled appropriately to ensure subject safety and data reliability. ⁵⁴ Finally, the language of the label information is set by the Member State concerned, and a product may be labeled in several languages. ⁵⁴

How the two regimes differ

The structural contrast is the headline. The FDA relies on a single, uniform warning plus a claims prohibition, and trusts sponsors to build in the identifying data needed to run the trial safely. The EU codifies that identifying data as a legal checklist, distinguishes immediate from outer packaging, and layers in blinding-preservation and expiry-relabeling controls that have no counterpart in the US text. A multinational sponsor running one protocol in both regions typically satisfies the FDA rule as a subset of what Annex VI already forces onto the label, then adds the exact US caution statement, rather than the other way round.

Practical implications for global trial labeling

For a sponsor labeling a common clinical supply for US and EU sites, three points drive the design. First, the mandatory US caution statement is jurisdiction-specific verbatim text and must be present on immediate packaging for US-destined units; it is not interchangeable with the EU "For clinical trial use only." ⁶⁰⁵¹ Second, the EU particulars list, including subject/treatment number, clinical trial reference code, storage conditions and an unambiguous period of use, is the binding floor for EU units and should generally be treated as the master content set. ⁵¹ Third, the EU expiry-change and blinding rules impose downstream GMP obligations (controlled overlabeling that preserves the batch number, shortest-dated expiry across a blinded kit) that the US rule does not spell out but that good practice will mirror anyway. ² Where authorized products are used as IMPs, the two systems diverge most: the EU allows normal marketed labeling with limited add-ons, whereas the US IND labeling and promotion controls continue to apply. ⁵⁴⁶¹